Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia

Phase 1 Completed 39 enrolled Millennium Pharmaceuticals, Inc.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety, tolerability, maximum tolerated dose and pharmacokinetics of MLN0128 in patients with Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia

Timeline

Start: 2010-11
Primary completion: 2013-05
Completion: 2013-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sapanisertib	Small molecule	—	Oral

Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia

Summary

Timeline

Drugs

Indications